STOCKS TELEGRAPH

Tag: Infinity Pharmaceuticals

  • Is There Any Reason As To Why The INFI Stock Rose Premarket?

    The shares of Infinity Pharmaceuticals Inc. (INFI) were up 8.11% to $2.4 in pre-market trading at the time of this writing. Monday’s session ended with INFI stock down -3.48% at $2.22. The volume for INFI stock was 4.75 million shares, a higher volume than the average daily volume of 2.07 million shares over the past 50 days.

    INFI stock has appreciated by 167.47% over the past 12 months but has fallen by -17.47% over the past week. The INFI stock has lost -31.69% over the past three months, and -43.80% over the past six months. In addition, INFI has a current market cap of $216.49 million, with 75.73 million outstanding shares. INFI stock is rising on the chart today ahead of a webinar.

    What will INFI Stock be presenting at the event?

    Biotech company Infinity is developing eganelisib (IPI-549), an intravenous, macrophage reprogramming medication with the potential to be a first-in-class immuno-oncology treatment. A number of clinical trials have shown that INFI stock treatment addresses a fundamental biological mechanism that suppresses the immune system.

    INFIS MARIO-275 is a randomized, controlled combination study that combines eganelisib with Opdivo for the treatment of urothelial cancer I/O naive patients. The INFI study MARIO-3 is the first combination study by INFI Stock to investigate eganelisib in front-line patients with advanced cancer.

    This morning at 8 am Eastern Time, Infinity will host a webinar for key opinion leaders.

    • INFI stock will discuss the MARIO-3 TNBC study and the MARIO-275 UC study, both of which add eganelisib to currently approved standard of care regimens.
    • As part of the MARIO-3 trial, eganelisib will be added to the combined regimen of Tecentriq and Abraxane which is approved as the standard of care for TNBC in the front-line setting.
    • The aim of MARIO-275 is to evaluate the addition of Eganelisib to approved standard of care Opdivo monotherapy in immuno-oncology-nave UC patients who have progressed on platinum therapy as a second line treatment.
    • A presentation by Erika P. Hamilton, M.D. will be featured during the webinar.
    • The latest data from MARIO-3, obtained by the Sarah Cannon Research Institute at Tennessee Oncology, will be discussed in relation to the current standard of care.

    What will INFI’s webinar cover?

    Following the formal presentation, Dr. Hamilton will be available to answer questions about preliminary MARIO-3 TNBC data in December 2020 at the 2020 San Antonio Breast Cancer Symposium. A status update on eganelisib in UC will be presented by Dr. Brian Schwartz, INFI Stock Consulting Chief Physician, based on preliminary data from the MARIO-275 Phase 2 study in second-line patients with UC.  Dr. Schwartz’s presentation will be based on the data which he presented at the 2021 ASCO Genitourinary Cancers Symposium in February 2021 and will be available to answer questions following the formal presentation.

  • 15 Trending Stocks in Biotechnology Industry

    15 Trending Stocks in Biotechnology Industry

    This year, biotech companies on the stock exchange have skyrocketed. This is no surprise since biotech firms are the leaders in the battle against the coronavirus pandemic. Even with Pfizer’s first vaccine in the UK, investors and pharmaceutical companies are well aware that the race is far ahead.
    Other diseases should not be ignored apart from coronavirus vaccines. The biotech sector is also creating headlines and innovating in areas linked to dementia, cancer, hereditary disorders, etc. Given the above, buyers are probably faced with the difficulty of choosing the best ones to purchase.

    Curis Inc. (NASDAQ:CRIS) shares were trading up 354.86% at $6.55 at the time of writing on Tuesday following announcement of proposed public offering of common stock.

    Curis Inc. (NASDAQ:CRIS) share price went from a low point around $0.62 to briefly over $3.59 in past 52 weeks, though shares have since pulled back to $6.55. CRIS market cap has remained high, hitting $409.70M at the time of writing, giving it price-to-sales ratio of more than 30.

    If we look at the recent analyst rating CRIS, Laidlaw initiated coverage on CRISshares with a Buy rating.

    Lexicon Pharmaceuticals Inc. (LXRX) last closed at $3.08, in a 52-week range of $1.03 to $5.33. Analysts have a consensus price target of $2.37. On November 17, 2020, the firmreported that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

    IGM Biosciences Inc. (IGMS) stock soar by 57.75% to $115.03 after declaringpricing of upsized $200 million public offering. The most recent rating by Robert W. Baird, on July 17, 2020, is at an Outperform.

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Shares headed rising, higher as much as 29.44%. The company will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) The most recent rating by Oppenheimer, on June 27, 2019, is at an Outperform.

    Oncternal Therapeutics Inc. (NASDAQ:ONCT) rose 27.64% after gaining more than $1.1 on Tuesday after reporting updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial.

    Proteostasis Therapeutics Inc. (PTI) last closed at $1.23, in a 52-week range of $0.87 to $4.72. The firm reported on November 16, 2020. a net loss of approximately $8.2 million for the three months ended September 30, 2020, as compared to a net loss of $12.8 million for the same period in the prior year.

    InflaRx N.V. (IFRX) stock soar by 18.27% to $4.79. The most recent rating by SVB Leerink, on November 06, 2020, is at an Outperform.

    Syros Pharmaceuticals Inc. (NASDAQ:SYRS) Shares headed rising, higher as much as 17.47% after closing $90.5 million strategic financing. The most recent rating by H.C. Wainwright, on November 04, 2020, is at a Buy.

    Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) rose 16.28% after gaining more than $0.28 on Tuesday.

    Ampio Pharmaceuticals Inc. (AMPE) last closed at $1.35, in a 52-week range of $0.31 to $1.39. The firm recently revealed that it will conduct its annual meeting in a virtual format only on December 12, 2020 at 9:00 am MST.

    Regulus Therapeutics Inc. (RGLS)stock soar by 15.19% to $0.93 following the closing of $19.4 million private placement of equity. The most recent rating by B. Riley FBR Inc., on March 28, 2018, is at a Neutral.

    Cancer Genetics Inc. (NASDAQ:CGIX) Shares headed rising, higher as much as 14.79%. The most recent rating by Maxim Group, on December 07, 2017, is at a Buy.

    Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) fall -11.85% after losing more than -$1.85 on Tuesday. The healthcare firm lately declared pricing of $70 million public offering of common stock, which is expected to close on or about December 10, 2020.

    iBio Inc. (IBIO) last closed at $1.31, in a 52-week range of $0.19 to $7.45 after declaring pricing of $35 million public offering of common stock. Analysts have a consensus price target of $2.00.

    Vaccinex Inc. (VCNX) stock soar by 14.08% to $2.35. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral.